Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Type 2 diabetes is a worldwide epidemic disease, and preventive strategies are needed to face
this health problem. The goal of this trial is to evaluate the effect of empagliflozin +
linagliptin + metformin + lifestyle on physiopathological parameters, sush as glucose
metabolism, insulin resistance, pancreatic beta cell function and cardiovascular function in
patients with impaired fasting glucose plus impaired glucose tolerance, during 12 months